Literature DB >> 31515942

Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality.

Eoin Donnellan1, Oussama M Wazni1, Walid I Saliba1, Bryan Baranowski1, Mazen Hanna1, Michael Martyn1, Divyang Patel1, Kevin Trulock1, Venu Menon1, Ayman Hussein1, Philip Aagaard1, Wael Jaber1, Mohamed Kanj1.   

Abstract

BACKGROUND: The aim of our study was to investigate outcomes of patients with ATTR (amyloidosis and transthyretin) CA (cardiac amyloidosis) and implantable devices with respect to left ventricular ejection fraction (LVEF), mitral regurgitation (MR), New York Heart Association (NYHA) functional class, and mortality.
METHODS: This was a retrospective observational cohort study of 78 patients with ATTR CA and implantable devices. During a mean follow-up of 42 months we investigated the impact of right ventricular (RV) pacing burden and biventricular (BiV) pacing on LVEF, MR severity, NYHA functional class, and mortality.
RESULTS: Worsening MR occurred in 11% of patients with a RV pacing % <40% compared to 62% of those with a RV pacing burden >40% (P = .002). Similarly, worsening LVEF occurred in 26% of patients who were RV paced <40% and 89% of those who were RV paced >40% of the time (P < .0001) and worsening in NYHA functional class occurred in 22% and 89%, respectively (P < .0001). Improvement in LVEF, NYHA functional class, and MR severity occurred in 78%, 67%, and 67%, respectively, in those with BiV devices. Death occurred in 67% of patients in the cardiac resynchronization therapy group compared to 68% of those with a RV pacing burden <40% and 92% of those with a RV pacing burden >40%.
CONCLUSION: A higher RV pacing burden is associated with deleterious remodeling and congestive heart failure in patients with ATTR CA, whereas BiV pacing is associated with improvements in LVEF, NYHA class, and degree of MR. BiV pacing should be considered in patients with ATTR CA and an indication for pacing. However, further larger prospective studies will need to be performed.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  biventricular pacing; cardiac amyloidosis; cardiac devices; device therapies; heart failure

Year:  2019        PMID: 31515942     DOI: 10.1111/jce.14180

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  15 in total

Review 1.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

Review 2.  Arrhythmias as Presentation of Genetic Cardiomyopathy.

Authors:  J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson
Journal:  Circ Res       Date:  2022-05-26       Impact factor: 23.213

Review 3.  Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Authors:  Vasiliki Bistola; John Parissis; Emmanouil Foukarakis; Pipitsa N Valsamaki; Aris Anastasakis; Georgios Koutsis; Georgios Efthimiadis; Efstathios Kastritis
Journal:  Heart Fail Rev       Date:  2021-01-15       Impact factor: 4.214

Review 4.  Arrhythmic Sudden Cardiac Death and the Role of Implantable Cardioverter-Defibrillator in Patients with Cardiac Amyloidosis-A Narrative Literature Review.

Authors:  Aleksandra Liżewska-Springer; Grzegorz Sławiński; Ewa Lewicka
Journal:  J Clin Med       Date:  2021-04-25       Impact factor: 4.241

5.  Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy.

Authors:  David Aouate; Aymeric Menet; Dimitri Bellevre; Thibaud Damy; Sylvestre Marechaux
Journal:  Eur Heart J Case Rep       Date:  2020-05-01

Review 6.  Advances in the Treatment of Cardiac Amyloidosis.

Authors:  Ariane Vieira Scarlatelli Macedo; Pedro Vellosa Schwartzmann; Breno Moreno de Gusmão; Marcelo Dantas Tavares de Melo; Otávio Rizzi Coelho-Filho
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

7.  Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis.

Authors:  Eoin Donnellan; Oussama M Wazni; Mazen Hanna; Mohamed Kanj; Walid I Saliba; Wael A Jaber
Journal:  J Am Heart Assoc       Date:  2020-07-07       Impact factor: 5.501

8.  Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.

Authors:  Diana Bonderman; Gerhard Pölzl; Klemens Ablasser; Hermine Agis; Stefan Aschauer; Michaela Auer-Grumbach; Christina Binder; Jakob Dörler; Franz Duca; Christian Ebner; Marcus Hacker; Renate Kain; Andreas Kammerlander; Matthias Koschutnik; Alexander Stephan Kroiss; Agnes Mayr; Christian Nitsche; Peter P Rainer; Susanne Reiter-Malmqvist; Matthias Schneider; Roland Schwarz; Nicolas Verheyen; Thomas Weber; Marc Michael Zaruba; Roza Badr Eslam; Martin Hülsmann; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-12-03       Impact factor: 1.704

Review 9.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

10.  Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis.

Authors:  Toshihide Izumida; Teruhiko Imamura; Makiko Nakamura; Koichiro Kinugawa
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.